ERBB2 and breast cancer: In 1989, Hudziak et al. isolated a monoclonal antibody named “4D5”, which has a high specificity toward HER2, from mice exposed to this receptor and showed its antiproliferative effects against SKBR3 HER2-positive BC cells [6].